Bradway Robert A 4

What Happened

• Robert A. Bradway, Chairman, CEO and President of Amgen Inc., had 5,057 shares disposed on May 2, 2026 to satisfy tax withholding obligations tied to equity awards.
• The dispositions were reported as: 2,631 shares withheld at $329.82 per share for $867,756, and 2,426 shares withheld at $329.82 per share for $800,143 — total proceeds/withholdings of $1,667,899.
• These transactions were tax-withholding/share-for-tax payments (Form 4 code F), not an open-market purchase.

Key Details

• Transaction date: May 2, 2026; filing date: May 5, 2026.
• Prices: $329.82 per share for both withholding events.
• Shares disposed: 2,631 and 2,426 (total 5,057).
• Shares owned after transaction: not disclosed in the filing.
• Footnote: The withholding included 1,624 Dividend Equivalents credited to unvested Restricted Stock Units under Amgen’s 2009 Equity Incentive Plan; DEs are paid out in shares on a one-to-one basis per the vesting schedule (plus cash for any fractional share).
• Filing status: filed on May 5, 2026 reporting May 2 transactions (filing timeliness not flagged as late in the notice).

Context

• These were routine share withholdings to satisfy tax obligations on vested awards and dividend equivalents. Such F-code dispositions are common when executives receive equity compensation and do not necessarily indicate a market-direction view.